Bioequivalence and Bioavailability Forum

Hi libaiyi,

❝ The design here is a three-period six-sequence William design. I just wondering when the study design is replicated, dose the power calculation method the same as what used in simple 2 by 2 cross over design? Thank you so much!

I am still somewhat baffled.
You have different SE's for the three comparisons, possibly suggesting that you are employing an EMA-style BE evaluation?

Anyways, if you are going for a 222BE design, then you can look at your MSE from the ANOVAs (plural, right?), convert them to CVs via CV=sqrt(exp(MSE)-1) and you have a decent variability estimate to plug in for any crossover design with or without scaling.

Your best point estimate is exp(-.2088)~0.81 with upper limit ~0.88, for the T-S pair. The others appear worse. I'd personally think twice, but I am widely known as a backward cowardly chicken.


Note, the opinion above implies logarithms and standard BE thinking.

---

Edit: Congratulations to your post № 1,500! [Helmut]